Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Detection Inks Benelux Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Detection today said that it has signed an agreement with Dutch firm Westburg BV to be the exclusive distributor of the firm's Detect-Ready MRSA panel in the Benelux region.

The Wayne, Pa.-based firm also said that the real-time PCR-based test has been CE-Marked for detection of both methicillin-resistant Staphylococcus aureus and methicillin-sensitive S, aureus. It said that the screening test enables physicians to distinguish the two types of infections.

"We anticipate launch in the Benelux region shortly, at which time our Detect-Ready MRSA panel will be available in 10 markets worldwide," David Wilson, MDI's VP for commercial operations, Europe, said in a statement.

The Detect-Ready MRSA panel is currently sold in the UK, Germany, Ireland, Switzerland, Spain, Austria, and Australia.

Financial and other terms of the agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.